Recipharm names 2016 International Environmental Award winner

Recipharm has announced that its 2016 International Environmental Award has been presented to Alistair Boxall, Professor in environmental science at the University of York, for his research into the impact of chemical contaminants on the environment and human health. 

Spanning more than two decades, Professor Alistair Boxall’s research has led to an improved understanding of the emerging ecological and health risks posed by chemical contaminants, including pharmaceuticals and nanoparticles, in the natural environment. In addition to his position at the University of York, he currently also serves as an academic coordinator of the Intelligent Assessment of Pharmaceuticals in the Environment (iPiE) project within the Innovative Medicines Initiative, and is also coordinator of the CAPACITIE project, which is currently exploring innovative methods for monitoring pollution in cities.

Lars Backsell, Chairman of the Board of Recipharm, commented: “We are delighted to present the 2016 award to Alistair Boxall. His work, which extends far beyond measuring concentration levels, has helped change attitudes and improve understanding of the detection, fate, effect and risks of contaminants on both human health and whole ecosystems. His research has been integral to building commitment towards environmental matters and is providing valuable guidance for future actions to decrease or avoid the negative effects of chemical contamination.”

Commenting on winning the award, Professor Boxall said: “I am delighted to receive the award. Our research on chemical contaminants has been a real team effort and the progress we have made wouldn’t have been possible without the hard work and commitment of my peers, students and postdocs. It is also a great testament to today’s research programmes that the pharmaceutical industry is recognising the importance of environmental impact and actively adapting practices to reduce the effects of contaminants and safeguard the environment.”


Contact information

Lars Backsell, Recipharm Chairman of the Board, +46 (0)8 602 52 00
Erik Haeffler, Vice President Manufacturing Services & Head of CSR, erik.haeffler@recipharm.com , +46 (0)8 6025 285
Alistair Boxall, alistair.boxall@york.ac.uk , +44 (0)190 432 4791

For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com , +44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com  

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden,  Telephone  +46 8 602 52 00

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links

Quotes

We are delighted to present the 2016 award to Alistair Boxall. His work, which extends far beyond measuring concentration levels, has helped change attitudes and improve understanding of the detection, fate, effect and risks of contaminants on both human health and whole ecosystems. His research has been integral to building commitment towards environmental matters and is providing valuable guidance for future actions to decrease or avoid the negative effects of chemical contamination.
Lars Backsell, Chairman of the Board of Recipharm
I am delighted to receive the award. Our research on chemical contaminants has been a real team effort and the progress we have made wouldn’t have been possible without the hard work and commitment of my peers, students and postdocs. It is also a great testament to today’s research programmes that the pharmaceutical industry is recognising the importance of environmental impact and actively adapting practices to reduce the effects of contaminants and safeguard the environment.
Alistair Boxall, Professor in environmental science at the University of York